Search

Your search keyword '"Flamholc L"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Flamholc L" Remove constraint Author: "Flamholc L" Topic male Remove constraint Topic: male
26 results on '"Flamholc L"'

Search Results

1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

3. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

4. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

5. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

6. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

7. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

8. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

9. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

10. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study

11. Liver-related death among HIV/hepatitis C virus-co-infected individuals

12. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

13. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

14. Infection-related and -unrelated malignancies, HIV and the aging population

15. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

16. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

17. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

18. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

19. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

20. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

21. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

22. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

23. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

24. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

25. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

26. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

Catalog

Books, media, physical & digital resources